We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Rhythm, Camurus Announce License Agreement

News   Jan 06, 2016

 
Rhythm, Camurus Announce License Agreement
 
 
Advertisement
 

RELATED ARTICLES

mRNA COVID-19 Vaccine Is Well-Tolerated and Generates Immune Response

News

A Phase 1 trial of an investigational mRNA vaccine to prevent SARS-CoV-2 infection has shown that the vaccine is well-tolerated and generates a strong immune response in older adults.

READ MORE

Computer Model Finds the Right Balance for Parkinson's Medication

News

As Parkinson's disease progresses, more levodopa is required to treat it. Too much, however, can lead to uncontrollable, involuntary bodily movements. To better understand the underlying reasons behind these effects, researchers created a model of the interactions between levodopa, dopamine, and the brain.

READ MORE

Phase 3 Trial Assesses Dual-Antibody Injection's Ability To Prevent SARS-CoV-2 Infection

News

A Phase III, randomized, double-blinded, placebo-controlled trial will help to determine if the dual-antibody treatment, REGN-COV2, can prevent infection in individuals who share a home with someone who has been diagnosed with COVID-19.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE